US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

pSivida

1.22

0.0000

Volume:- -

Turnover:- -

Market Cap:55.21M

PE:-2.35

High:1.22

Open:1.22

Low:1.22

Close:1.22

52wk High:2.45

52wk Low:0.9300

Shares:45.26M

Float Shares:24.86M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5200

ROE:--

ROA:--

PB:5.57

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

pSivida

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.psivida.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PSDV/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"PSDV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSDV\",,,,,undefined,":{"symbol":"PSDV","market":"US","secType":"STK","nameCN":"pSivida","latestPrice":1.22,"timestamp":1522353600000,"preClose":1.22,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":24860000,"shares":45257000,"eps":-0.52,"marketStatus":"Closed President's Day","change":0,"latestTime":"03-29 16:00:00 EDT","open":1.22,"high":1.22,"low":1.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.52,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSDV\",,,,,undefined,":{"symbol":"PSDV","floatShares":24860000,"roa":"--","roe":"--","lyrEps":0,"shares":45257000,"dividePrice":0,"high":1.22,"amplitude":0,"preClose":1.22,"low":1.22,"week52Low":0.93,"pbRate":"5.57","week52High":2.45,"institutionHeld":0.3409,"latestPrice":1.22,"eps":-0.52,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.52,"open":1.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSDV\",params:#limit:5,,,undefined,":[{"date":"2018-04-02","symbol":"PSDV","newSymbol":"EYPT","type":"symbolChange","dateTimestamp":1522641600000},{"market":"US","date":"2018-02-07","symbol":"PSDV","fiscalQuarterEnding":"2017/12","expectedEps":-0.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1517979600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2017-11-07","symbol":"PSDV","fiscalQuarterEnding":"2017/09","expectedEps":-0.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1510030800000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2017-09-11","symbol":"PSDV","fiscalQuarterEnding":"2017/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1505102400000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2017-05-04","symbol":"PSDV","fiscalQuarterEnding":"2017/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1493870400000,"reportTimeType":"post","actualEps":-0.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSDV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSDV\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.psivida.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Medidur, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Its pre-clinical development program focuses on developing products using its core platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.","exchange":"NASDAQ","name":"pSivida","nameEN":"pSivida"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PSDV\",market:\"US\",,,undefined,":null}}